Under Armour has reached a 15-year deal with UCLA worth $280 million, which is the largest ever deal in college sports history. The FMHR traders discuss the value in the stock. » Read More
Under Armour fan and Morningstar Equity Analyst Paul Swinand sifts through UA's quarterly results and weighs in on the company's outlook as competition heats up in the athleisure space.
Amid earning season, Estimize takes a look at the names that are anticipated to surprise either to the upside or downside this week.
Johnny Manziel's career has gone from bad to worse. Nike confirmed to CNBC that the former Heisman Quarterback was no longer a Nike athlete.
Meet power couple Kevin and Maggie Callahan. Under Armour paid $150 million for Kevin's app, and Maggie's latest venture is booming.
Under Armour shares took a hit Monday, and "Fast Money" traders contended the stock's prospects may not improve soon.
The Halftime Report experts debate Morgan Stanley's call to sell Under Armour
Some of the names on the move ahead of the open.
Kevin Plank, Under Armour Founder & CEO, talks about his entrepreneurship competition the Cupid's Cup, as well as the health of business and competitiveness in the U.S.
CNBC's Dominic Chu looks at whether professional athletes actually boost brands, after news Under Armour will be selling Jordan Spieth-style shoes.
The first quarter roller-coaster ride has finished its round trip and markets are heading into the historically dull second quarter. Here's how to trade it.
A few heavily shorted stocks have rallied this year, and some "Fast Money" traders believe those names could keep climbing.
Richard Ross, Managing Director and Head of Technical Analysis, Evercore ISI, looks at three of the most hated stocks that are on the verge of a breakout.
The "Fast Money" traders give you 4 names to trade on short interest.
Masters champion Jordan Spieth talks this year's tourney, the need to step it up and the latest from his deal with Under Armour.
Jim Cramer provides his thoughts on why investors should stay cautious when speculating in the biotech sector
Because of its duration, tournament time has an impact on some companies that should be reflected next quarter. Estimize reports.
Sam Poser, Senior Research Analyst at Sterne Agee, and Susan Anderson, Retail Analyst an Vice President at FBR Capital Markets, debate whether or not to buy into Nike after shares in the company fell after reporting weak sales.
There is one element in Nike's quarterly report that has CNBC's Jim Cramer concerned.
Nike shares fell on Wednesday, after the athletic wear company reported revenues that missed Wall Street expectations.
Jim Cramer explains what to watch ahead of the open, including Nike and Lululemon.